Risk factors for melanoma among survivors of non-Hodgkin lymphoma
the ONA take:
Investigators sought to quantify risks associated with specific treatments and immune-related risk factors for cutaneous melanoma among survivors of non-Hodgkin lymphoma.
This research follows previous studies that reported that survivors of non-Hodgkin lymphoma (NHL) have an increased risk of developing cutaneous melanoma.
Risk of second melanoma was evaluated in 44,870 1-year survivors of first primary NHL. A total of 202 second melanoma cases were identified among the survivors, including 91 after chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 111 after other NHL subtypes.
This research revealed a significantly increased risk of melanoma among survivors of CLL/SLL who received infused fludarabine-containing chemotherapy with or without rituximab. Risk of melanoma was not associated with specific treatments among survivors of other subtypes of NHL.
The investigators conclude that immune perturbation may contribute to risk of melanoma after CLL/SLL. Survivors of NHL should be vigilantly followed to ensure early detection of melanoma.
Survivors of non-Hodgkin lymphoma have an increased risk of developing cutaneous melanoma.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|